Subjects are eligible for the study if they meet all of the following

Inclusion Criteria:

- Diagnosis of one of the following hematologic malignancies not responding to at least
2 standard treatment regimens. Any criteria for persistent or recurrent disease
acceptable, i.e. ≥5% blasts for acute leukemia.

- acute lymphoblastic leukemia (ALL)

- acute myeloid leukemia (AML)

- non-Hodgkin's lymphoma (NHL)

- Hodgkin's lymphoma (HL)

- multiple myeloma (MM)

- chronic lymphocytic leukemia (CLL)

- Performance status - Karnofsky > 50% for patients > 10 years of age or Lansky >50%
for patients < 10 year of age

- Normal organ function within 14 days of study entry

- If female and of childbearing potential, are willing to use adequate contraception
(hormonal, barrier method, abstinence) prior to study entry and for the duration of
study participation. A female is considered to be of childbearing potential unless
she has had her uterus removed, had a double oophorectomy, or has been amenorrheic
for at least 6 months after chemotherapy

Exclusion Criteria:

- Had/have the following prior/concurrent therapy:

- Systemic corticosteroids (oral or injectable) within 7 days of first dose of
852A (topical or inhaled steroids are allowed)

- Investigational drugs/agents within 14 days of first dose of 852A

- Immunosuppressive therapy, including cytotoxic agents within 14 days of first
dose of 852A (nitrosoureas within 30 days of first dose)

- Drugs known to induce QT interval prolongation and/or induce Torsades De Pointes
unless best available drug required to treat life-threatening conditions

- Radiotherapy within 4 weeks of the first dose of 852A

- Hematopoietic cell transplantation 4 weeks of first dose of 852A

- Active infection or fever > 38.5°C within 3 days of first dose of 852A

- Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by
medication

- History of, or clinical evidence of, a condition which, in the opinion of the
investigator, could confound the results of the study or put the subject at undue
risk

- Uncontrolled intercurrent or chronic illness

- Active autoimmune disease requiring immunosuppressive therapy within 30 days

- Active hepatitis B or C with evidence of ongoing viral replication

- Hyperthyroidism

- Uncontrolled seizure disorder

- Active coagulation disorder not controlled with medication

- Pregnant or lactating

- Concurrent malignancy (if in remission, at least 5 years disease free) except for
localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas
adequately treated

- Proven active central nervous system (CNS) disease

- Human Immunodeficiency Virus (HIV) positive

- Congenital long QT syndrome or abnormal baseline QTc interval (> 450 msec in males
and > 470 msec in females) after Bazett's correction (QTc msec = QT msec / square
root of the RR interval in seconds) on screening electrocardiogram (ECG).